Cancer GENETICS AND EPIGENETICS

项目总结： 癌症遗传学和表观遗传学(CGE)计划的目标是更好地了解遗传和表观遗传学不稳定性的基本机制及其在人类肿瘤发生和发展中的作用。为了追求这一目标，该计划将其研究工作组织到三个重点领域：1)DNA损伤和修复与基因组不稳定；2)表观遗传学和基因调控；3)癌症遗传学/基因组学。 CGE项目由来自埃默里大学13个学术部门和3所学校的29名核心成员组成，其中包括医学院、公共卫生学院和埃默里学院。CGE计划成员目前有15,110,592美元的研究资助(年度直接成本)，其中12,849,105美元是同行评审，4,277,290美元(34%)是NCI资助的。项目成员在当前项目期间出版了227种与癌症相关的出版物。其中，12%和25%分别代表方案内和方案间的相互作用。 在目前的项目期间，发现工作已经导致确定了其突变或表达改变有助于癌症启动和进展的关键基因。癌症表观遗传学领域的基本发现促进了早期小分子筛选工作，以确定新的靶向制剂。 在人类辐射致癌、DNA损伤/修复和癌症基因组学领域，方案制定和关键招聘加强了方案内的活动。这已被用于几个新的多研究者赠款，并通过增加方案间活动和跨领域基因组学倡议为该计划提供了关键的转化途径。基因组学研究的成功导致了肿瘤的分子分类和基因、基因的鉴定 前列腺癌、乳腺癌、脑癌和肺部恶性肿瘤的特征和临床预后因素。癌症遗传学和表观遗传学计划促进了科学合作和癌症研究发现，并已定位为在即将到来的项目期继续发展。

PROJECT SUMMARY: The goal of the Cancer Genetics and Epigenetics (CGE) Program is to better understand the fundamental mechanisms underlying genetic and epigenetic instability and its contribution to the initiation and progression of human tumors. In pursuit of this goal, the program organizes its research efforts into three areas of focus: 1) DNA damage and repair and genome instability; 2) epigenetics and gene regulation; and 3) cancer genetics /genomics. The CGE Program consists of 29 core members from 13 academic departments and three schools across Emory University, including the School of Medicine, the School of Public Health and Emory College. CGE Program members currently have $15,110,592 in research grant funding (annual direct costs), of which $12,849,105 is peer-reviewed and $4,277,290 (34%) is NCI-funded. Program members have published 227 cancer-related publications in the cun-ent project period. Among these, 12% and 25% represent intra- and inter-programmafic and interactions, respectively. In the current project period, discovery efforts have led to the identification of key genes whose mutation or altered expression contribute to cancer initiation and progression. Basic discoveries in the area of cancer epigenetics have prompted early small molecule screening efforts to identify novel targeted agents. Program development and key recruitments have strengthened and enhanced intra-programmatic activities in the areas of human radiation carcinogenesis, DNA damage/repair, and cancer genomics. This has been leveraged into several new multi-investigator grants and has provided key translational avenues for the program through increased inter-programmatic activities and cross-cutting genomics initiatives. Successful genomic studies resulted in the molecular classification of tumors and the identification of genes, gene signatures, and clinical factors with prognostic value in prostate, breast, brain, and lung malignancies. The Cancer Genetics and Epigenetics Program facilitates scientific collaborations and cancer research discoveries and has positioned itself for continued development in the forthcoming project period.